Diabetes Management during the COVID-19 Pandemic: An Iranian Expert Opinion Statement

Arch Iran Med. 2020 Aug 1;23(8):564-567. doi: 10.34172/aim.2020.61.

Abstract

The coronavirus infection is an evolving pandemic with high morbidity and mortality, especially in people with comorbidities. The case fatality rate (CFR) is 9.2% in the presence of diabetes, while it is 1.4% in those without any comorbidity. Diabetes is a prevalent disease globally; hence, healthcare professionals are highly concerned about severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic progression. Current evidence does not support higher incidence of coronavirus disease 2019 (COVID-19) in people with diabetes (PWD). However, people with diabetes are considered high risk for developing complications. Optimal metabolic control is a challenging concept, especially in the presence of an acute and severe respiratory viral infection. In this consensus, we considered the challenging issues in management of patients with diabetes during the COVID-19 pandemic. The consensus covers various aspects of outpatient as well as inpatient care based on the current evidence.

Keywords: COVID-19; Diabetes Management; Expert Opinion.

MeSH terms

  • Betacoronavirus*
  • COVID-19
  • Communicable Disease Control / organization & administration*
  • Coronavirus Infections / complications*
  • Coronavirus Infections / epidemiology
  • Coronavirus Infections / therapy*
  • Diabetes Mellitus / therapy*
  • Diabetes Mellitus / virology
  • Humans
  • Iran
  • Pandemics
  • Pneumonia, Viral / complications*
  • Pneumonia, Viral / epidemiology
  • Pneumonia, Viral / therapy*
  • SARS-CoV-2